Related Experiment Video

Updated: Jul 10, 2026

Rat Mesentery Angiogenesis Assay
18:30

Rat Mesentery Angiogenesis Assay

Published on: June 18, 2011

Peroxovanadium compounds as inhibitors of angiogenesis

C J Doillon1, R L Faure, B I Posner

  • 1Oncology and Molecular Endocrinology, Laval University Medical Center and Laval University, Ste-Foy, Quebec, Canada. charles.doillon@crchul.ulaval.ca

Angiogenesis
|October 1, 2003
PubMed

Insights

Two peroxovanadium compounds, bpV(phen) and bpV(pic), significantly inhibited endothelial cell growth and organization. bpV(phen) demonstrated potent angiostatic properties, effectively inhibiting angiogenesis in chick embryos.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Angiogenesis is crucial for development and disease, involving endothelial cell activation via signaling pathways like tyrosine phosphorylation.
  • Phosphotyrosyl phosphatase (PTP) inhibitors are being explored for their therapeutic potential.

Purpose of the Study:

  • To investigate the angiogenic properties of two peroxovanadium-based PTP inhibitors: potassium bisperoxo(1,10-phenanthroline)oxovanadate(V) [bpV(phen)] and potassium bisperoxo(pyridine-2-carboxylato)oxovanadate(V) [bpV(pic)].
  • To assess the impact of these inhibitors on endothelial cell behavior and angiogenesis.

Main Methods:

  • In vitro studies using cell monolayer and 3D culture systems to evaluate endothelial cell growth, organization, and differentiation.
  • Rat aortic ring assay to assess the effect on cell migration.
  • Chick embryo angiogenesis assay to determine in vivo anti-angiogenic activity.

Main Results:

  • Both bpV(phen) and bpV(pic) markedly interfered with endothelial cell growth, organization, and differentiation in cell culture models.
  • The observed effects were dose-dependent and influenced by the ancillary ligand.
  • Low-dose bpV(phen) significantly inhibited cell migration in the rat aortic ring assay.
  • bpV(phen) proved to be a potent inhibitor of angiogenesis in the chick embryo assay, exhibiting strong angiostatic properties at low concentrations.

Conclusions:

  • Peroxovanadium compounds, specifically bpV(phen) and bpV(pic), possess significant anti-angiogenic and anti-endothelial cell activity.
  • bpV(phen) is a potent angiostatin with therapeutic potential for conditions involving excessive angiogenesis.

More Related Videos

HUVEC Tube-formation Assay to Evaluate the Impact of Natural Products on Angiogenesis06:12

HUVEC Tube-formation Assay to Evaluate the Impact of Natural Products on Angiogenesis

Published on: June 24, 2019

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Related Concept Videos

Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...